SHANGHAI HILE BIO-TECHNOLOGY CO LTD Class A

SHANGHAI HILE BIO-TECHNOLOGY CO LTD Class A

SSSE:603718
2.82
CNY
-0.08
(-2.76%)
-0.46EPS
2.01BMarket Cap

Total Valuation

CNY

As of September 30, 2026, SHANGHAI HILE BIO-TECHNOLOGY CO LTD Class A carries a market capitalization of 2.01B, placing it among publicly traded companies globally. Its enterprise value stands at 1.91B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.01B
Enterprise Value1.91B

Share Statistics

As of September 30, 2026, SHANGHAI HILE BIO-TECHNOLOGY CO LTD Class A has 648.98M shares outstanding.

Shares Outstanding648.98M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 7.19, and the price-to-book ratio stands at 2.22.

PS Ratio7.19
PB Ratio2.22
P/TBV Ratio6.85

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 6.89 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.91B versus a market cap of 2.01B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales6.89

Financial Position

As of September 30, 2026, SHANGHAI HILE BIO-TECHNOLOGY CO LTD Class A maintains a current ratio of 3.43, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.57, indicating elevated leverage, while an interest coverage ratio of -208.04 demonstrates limited ability to service its debt obligations.

Current Ratio3.43
Quick Ratio1.74
Debt / Equity11.57
Debt / EBITDA-0.19
Interest Coverage-208.04

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, SHANGHAI HILE BIO-TECHNOLOGY CO LTD Class A posted a negative return on equity (ROE) of -24.96, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -19.44, reflecting losses generated across the asset base. The company generates approximately 815,189.75 in revenue per employee across its workforce of 340.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.18 indicates how many times SHANGHAI HILE BIO-TECHNOLOGY CO LTD Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-24.96
Return on Assets (ROA)-19.44
Revenue Per Employee815,189.75
Employee Count340.00
Inventory Turnover1.18

Taxes

CNY

Over the twelve months ended September 30, 2026, SHANGHAI HILE BIO-TECHNOLOGY CO LTD Class A recorded 106.31M in income tax expense. The company reported a pretax loss of -190.47M and -310.01M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax106.31M

Stock Price Statistics

CNY

As of the close on November 17, 2026, SHANGHAI HILE BIO-TECHNOLOGY CO LTD Class A's stock has declined approximately 59.94% over the past 52 weeks. The 50-day moving average sits at 3.02, while the 200-day moving average is 3.71.

52-Week Price Change-59.94%
50-Day Moving Average3.02
200-Day Moving Average3.71

Income Statement

CNY

Over the twelve months ended September 30, 2026, SHANGHAI HILE BIO-TECHNOLOGY CO LTD Class A generated 277.16M in revenue and converted that into -310.01M in net income, yielding earnings per share of -0.46. EBITDA reached -588.19M, while operating income came in at 57.51M.

Revenue277.16M
Gross Profit175.73M
Operating Income57.51M
Pretax Income-190.47M
Net Income-310.01M
EBITDA-588.19M
EBIT-588.19M
Earnings Per Share (EPS)-0.46

Balance Sheet

CNY

As of September 30, 2026, SHANGHAI HILE BIO-TECHNOLOGY CO LTD Class A holds 290.09M in cash and equivalents against 113.74M in total debt, resulting in a net debt position of -37.39M. Total book value stands at 902.33M, with working capital of 405.38M providing operational flexibility.

Cash & Cash Equivalents290.09M
Total Debt113.74M
Net Debt-37.39M
Equity (Book Value)902.33M
Book Value Per Share1.39
Working Capital405.38M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-14.90M

Margins

Over the twelve months ended September 30, 2026, SHANGHAI HILE BIO-TECHNOLOGY CO LTD Class A posted a gross margin of 63.40, reflecting its pricing power and cost economics. The operating margin of 20.75 and net profit margin of -111.85 provide insight into operational efficiency.

Gross Margin63.40
Operating Margin20.75
Pretax Margin-68.72
Profit Margin-111.85
EBITDA Margin-212.22

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, SHANGHAI HILE BIO-TECHNOLOGY CO LTD Class A paid dividends of 0.11 per share. The dividend payout ratio of -25.95 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 3.28, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to SHANGHAI HILE BIO-TECHNOLOGY CO LTD Class A shareholders.

Dividend Per Share0.11
Payout Ratio-25.95
Shareholder Yield3.28

Stock Splits

SHANGHAI HILE BIO-TECHNOLOGY CO LTD Class A's most recent stock split took place on May 5, 2016 with a 100:253 split ratio.

Last Split Date5/5/2016
Split Ratio100:253

Scores

As of September 30, 2026, SHANGHAI HILE BIO-TECHNOLOGY CO LTD Class A has an Altman Z-Score of 4.70, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.70